Revance Therapeutics Inc (RVNC)

24.15
0.40 1.70
NASDAQ : Health Care
Prev Close 23.75
Open 23.60
Day Low/High 23.00 / 24.20
52 Wk Low/High 12.54 / 42.41
Volume 230.65K
Avg Volume 211.40K
Exchange NASDAQ
Shares Outstanding 30.27M
Market Cap 690.24M
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Positive BELMONT Phase 2 Trial Results Published In Dermatologic Surgery

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced the electronic publication (ePub) of its...

Revance Reports Additional Positive Week 24 Efficacy Results From RT002 Injectable Phase 2 Cervical Dystonia Trial

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced additional clinical results from its U.

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming...

Revance Announces Positive Top-Line 24-Week Duration Of Effect Results In All Three Cohorts In RT002 Injectable Phase 2 Cervical Dystonia Trial

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced duration of effect of at least 24 weeks in its...

Revance Releases First Quarter 2017 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31,...

Revance Provides Update On Phase 2 Program For RT002 Injectable In The Management Of Plantar Fasciitis

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that it is expanding the Company's Phase 2...

Revance Therapeutics To Release First Quarter 2017 Financial Results Tuesday, May 9, 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2017...

Revance Completes Enrollment In Phase 3 Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of patient enrollment in two pivotal...

Revance Announces BELMONT Phase 2 Clinical Data To Be Presented At The 2017 American Academy Of Dermatology (AAD) Annual Meeting

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the company's...

Revance Releases Fourth Quarter And Full Year 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the fourth quarter and full year ended...

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming...

Revance Therapeutics To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter 2016...

BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017

BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the company's...

Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017

Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentations of clinical data for DaxibotulinumtoxinA...

Revance Provides Clinical Milestones And Financial Outlook For 2017

Revance Provides Clinical Milestones And Financial Outlook For 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today defined key 2017 clinical milestones for DaxibotulinumtoxinA for...

Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial

Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced positive interim results from its U.

Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines

Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of subject dosing in the company's SAKURA...

Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference

Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 28 th Annual...

Revance To Participate In The Jefferies 2016 London Healthcare Conference

Revance To Participate In The Jefferies 2016 London Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Jefferies 2016...

Revance Releases Third Quarter 2016 Results

Revance Releases Third Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the third quarter ended September 30, 2016.

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of a Phase 2 placebo-controlled trial of its...

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release third quarter 2016...

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Investors considering a purchase of Revance Therapeutics Inc shares, but tentative about paying the going market price of $15.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $10 strike, which has a bid at the time of this writing of 55 cents.

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells...

Revance Releases Second Quarter 2016 Results

Revance Releases Second Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the second quarter ended June 30, 2016.

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016...

These 5 Stocks Are Primed for Breakouts

These 5 Stocks Are Primed for Breakouts

Here's a technical look at how to trade five stocks triggering breakout trades.

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its Type B / pre-IND / pre-Phase 3...